Skip to content

Author

Yang Li

We have 2 of 9 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation

Antibody-drug conjugates (ADCs) have established targeted payload delivery as an important anticancer strategy, but their efficacy remains constrained by antigen heterogeneity, incomplete internalisation, resistance and dose-limiting toxicity. Bispecific antibody-drug conjugates (BsADCs) add a second antigen- or epitop...

Yang Li, Yu Li, Rong-Fong Huang et al. · 0 citations
#gene editing Review Open access Sep 2026

Engineering strategies to address immune and delivery barriers in pancreatic ductal adenocarcinoma: a barrier-matched translational framework

This review evaluates oncolytic virotherapy, gene-editing technologies, engineered immune-cell therapies, nanotechnology-enabled delivery systems, and artificial intelligence-assisted precision oncology according to the PDAC barriers they are intended to address and the maturity of the supporting evidence.

Yang Li, Yu Li, Jia Fan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.